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ABSTRACT
Despite the great potential of RNAi, ectopic expres-
sion of shRNA or siRNAs holds the inherent risk of
competition for critical RNAi components, thus
altering the regulatory functions of some cellular
microRNAs. In addition, specific siRNA sequences
can potentially hinder incorporation of other siRNAs
when used in a combinatorial approach. We show
that both synthetic siRNAs and expressed shRNAs
compete against each other and with the endogen-
ous microRNAs for transport and for incorporation
into the RNA induced silencing complex (RISC). The
same siRNA sequences do not display competition
when expressed from a microRNA backbone. We
also show that TAR RNA binding protein (TRBP)
is one of the sensors for selection and incorporation
of the guide sequence of interfering RNAs.
These findings reveal that combinatorial siRNA
approaches can be problematic and have important
implications for the methodology of expression and
use of therapeutic interfering RNAs.
INTRODUCTION
The phenomenon of RNA interference was ﬁrst observed
almost a decade ago (1) and seems to have evolved as a
defense mechanism against foreign double-stranded RNA.
It is triggered by short RNA duplexes ( 21–23nt in
length), which are processed from longer double-stranded
RNA transcripts (2,3). Two major classes of small double-
stranded RNA molecules have thus far been identiﬁed:
small interfering RNAs (siRNAs) and microRNAs
(miRNAs). SiRNAs are fully complementary double-
stranded molecules while miRNAs originate as duplexes
that have bulges. Both classes of double-stranded
RNAs assemble in the RNA induced silencing complex
(RISC), which contains key proteins for the processing
and functioning of double-stranded RNAs in RNAi.
A member of the Argonaute family, Ago-2, has been
identiﬁed as the catalytic core of this complex (4–8).
Since their discovery, the use of siRNAs has quickly
widened to diverse areas of research and as potential
therapeutic agents (9). High-throughput analysis based on
the use of siRNA libraries is also revolutionizing the ﬁeld
of functional genomics (9–11). However, RNAi is an
important component of endogenous cellular processes
(12) involved in post-transcriptional regulation of endo-
genous gene expression (13,14) as well as antiviral
protection (15–18). Interfering with the endogenous
functions of RNAi could lead to severe toxicity as recently
demonstrated (19).
The key component for the cellular export of shRNAs
and microRNAs is the nuclear karyopherin Exportin-5
(20–23). In the presence of Ran-GTP, Exportin-5 binds
to both shRNAs and microRNAs transporting them
from the nucleus to the cytoplasm. Exportin-5 is a
saturable transport pathway so the excessive production
of small interfering RNAs could result in a decrease of
cellular miRNA function (19,24). This export function is
not required for the activity of synthetic siRNAs (20).
In this work, we show that the competition between
shRNAs with cellular miRNAs is a general phenomenon
that also takes place with synthetic siRNA sequences. The
ability to compete varies with the sequence and does not
depend solely on the saturation of Exportin-5. We show
that siRNAs, which do not depend on Exportin-5 for their
transport to the cytoplasm, retain their ability to compete
against shRNAs and microRNAs. Ectopic expression of
Exportin-5 only partially relieves the competition between
shRNAs and endogenous miRNAs or exogenous siRNAs.
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not ectopically expressed microRNAs are able to interfere
with each other and with the endogenous microRNA
pathway through their ability to be incorporated into
RISC. However, the relative strength of competition can
be equalized for all the tested siRNA sequences by
reducing the cellular concentration of the HIV-1 TAR
RNA binding protein (TRBP). Thus, our results suggest
that TRBP is a sensor in the loading of the RNA guide
sequence into RISC.
MATERIALS AND METHODS
ShRNAs and MicroRNAs constructions
U6shRNA-expressing constructs were synthesized via a
PCR-based reaction that includes primers encoding the
shRNA with a 30 region complementary to the U6
promoter and a primer complementary to the 50 end of
the U6 promoter as described previously (25). All PCR
reactions were carried out as follows: 1min at 948C, 1min
at 558C and 1min at 728C for 30 cycles. The resulting
PCR cassettes were cloned directly into the pCR2.1
plasmid (TA cloning vector, Invitrogen). The shRNA
constructs used for the competition experiments are
targeted against sequences present in the HIV-rev (shSII
and shSI) HIV tat (shSI, shTAT), HIV vif (shVif) and the
EnvPb1 retrovirus envelope (shL) genes. The shRNA Luc
(Luc) is targeted to a sequence present in the coding region
of the ﬁreﬂy luciferase gene. All shRNAs are expressed
by transcription from the U6 promoter. The synthetic
siRNAs (siH3, siH6 and siH1) are targeted against
sequences present in the coding region of the hnRNPH
gene. Refer to the Supplementary Information for speciﬁc
sequences for the shRNAs and siRNAs. All other
oligonucleotide sequences are available upon request.
The microRNA constructs were similarly constructed
using overlapping primers containing the wild type or a
variant mir30 sequence. The mir30 guide sequence was
replaced with 21nt complementary to a site present in the
HIV-rev transcript (SII) by including the corresponding
nucleotide mutations in the PCR primers. The resulting
PCR products were cloned into pcDNA3.1 under the
control of the CMV promoter.
A cassette containing the U1 promoter, the ﬁreﬂy
luciferase coding sequence, and the SV40 polyadenylation
signal was digested with EcoRI and DraII and cloned into
the Bluescript vector (Stratagene) to create the ﬁreﬂy
luciferase target (FLT).
The Renilla luciferase target (RLT) was generated by
cloning a 21-nt HIV-rev sequence (SII) into the XhoI
site located in the 30-untranslated region (30-UTR)
of the humanized Renilla luciferase gene of plasmid
psiCHECK-2
TM (Promega).
Cell linesand transfection conditions
Cells were grown in DMEM (Irvine Scientiﬁc, Santa Ana,
CA, USA) supplemented with 10% fetal calf serum
(Irvine Scientiﬁc), 1mM L-glutamine. To generate the
HCT116-GFPmiR21 cell line, HCT116 cells were trans-
fected (using Lipofectamine 2000, Invitrogen) with SapI
linearized pcDNA4/GFPmir21 plasmid DNA (4) (gen-
erous gift from Thomas Tuschl) and cells with stable
plasmid integrations were selected by applying 200mg
Zeocin per ml media for 10 days. Single colonies were
picked and screened for expression of EGFP upon
transfection with a 20O-methyl RNA complementary to
miR21 relative to a control 20O-methyl RNA complemen-
tary to miR33.
For the competition experiments, 293 cells were
transfected with the shRNA expression constructs
and the corresponding targets in 24-well plates using
Lipofectamine Plus
TM reagent (Life Technologies,
GibcoBRL) as described by the manufacturer. One
hundred nanogram of the FLT plasmid was co-transfected
with 12.5, 25, 50 or 100ng of the shRNA-expressing
constructs and 0.2ng of the Renilla luciferase plasmid
which was included to normalize for transfection eﬃciency
for each reaction. The synthetic siRNAs were transfected
to achieve 10 nanomolar concentrations in all co-
transfection experiments. However, 100 nanomolar con-
centrations of each siRNA were used for transfection in
the HCT116-GFPmiR21 cell line. One hundred nanomo-
lar concentrations of the 20O-Me oligonucleotides were
also used for transfection in this cell line.
One hundred nanogram of the microRNA constructs
were co-transfected with 20, 50 or 100ng of RTL and
yielded the same relative results in each case. Here, 0.5ng
of ﬁreﬂy luciferase were used to normalize for transfection
eﬃciency in each sample. However, 800ng of both the
shRNAs and the microRNAs were used for the transfec-
tions in the HCT116-GFPmiR21 cell line.
For the overexpression of Exportin-5, 100ng of an
Exportin-5 expression plasmid (kindly provided by
Thomas Tuschl) was co-transfected with 100ng of the
FLT plasmid and 50ng of each shRNA construct.
Ten (or) twenty nanomolar of each synthetic siRNA
were also used for this experiments and yielded analogous
results.
The TRBP down-regulation was achieved by transfect-
ing 40nM of anti-TRBP siRNAs (26) (siTRBP-A
siTRBP-B and siTRBP1; sequences are available upon
request) in a 100mm plate of 293 cells. Cells were
transfected in suspension at  50% conﬂuency using the
siQuest transfection reagent (Mirus, Madison, WI, USA)
as suggested by the manufacturer. The following day cells
reached  70% conﬂuency and were transfected a second
time using the siQuest transfection reagent. Twenty-four
hours after the second transfection, cells were lifted,
seeded in a 24-well plate, and transfected with the various
constructs as described in the Results section. Cells were
lysed 24h after this ﬁnal transfection and processed for
luciferase assays.
Each experimental sample was normalized against its
own target control, which included the corresponding
target co-transfected with one or more irrelevant controls.
For example, down-regulation of the FLT by the U6
anti-luciferase shRNA (Luc) was calculated by comparing
the luciferase down-regulation obtained with the Luc-
speciﬁc shRNA to the luciferase units obtained when the
target was co-transfected with an irrelevant shRNA.
When speciﬁc shRNAs were co-transfected with
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obtained when the target was co-transfected with irrele-
vant shRNA and the microRNA controls. Similarly the
impairment of Luc activity by the synthetic oligonucleo-
tides was determined by comparing the luciferase units
with those obtained when the luciferase target was
transfected with only the irrelevant synthetic siRNA.
It is important to normalize the experimental samples to
their speciﬁc controls since si, sh or microRNA constructs
co-transfected with a target could non-speciﬁcally alter the
results by increasing or decreasing the expression of that
target. All the experiments were normalized for transfec-
tion eﬃciency, carried out in duplicate, and repeated a
minimum of three times. Diﬀerent amounts of Bluescript
plasmid (Stratagene) were added to all the transfections to
obtain the same total amount of DNA transfected in each
experiment, which corresponded to 400ng per reaction
(1ml Lipofectamine-2000) except for the transfections
in the HCT116-GFPmiR21 cell line in which the
total amount of transfected DNA was 800ng (2ml
Lipofectamine-2000; no Bluescript was added). The cells
were analyzed for luciferase or EGFP expression 48h
following transfections.
Luciferase assays
A total of 293 cells were seeded in 24-well plates and
transfected the next day at 80% conﬂuency. Twenty-four
or 48h post-transfection, the medium was removed and
cells were washed once with DPBS (Dulbecco’s Phosphate
Buﬀer Saline, Cellgro). One hundred microliter of 1 
Passive Lysis Buﬀer (Promega) was then added to each
well. Cells were lysed at room temperature with gentle
shaking for 20min. Ten microliter of cell lysates were
assayed for dual luciferase activity according to the
manufacturer’s instructions (Dual Luciferase Reporter
System, Promega). Changes in the levels of the FLT were
calculated after normalization against the Renilla lucifer-
ase units. When the Renilla luciferase was used as the
target, changes in expression were calculated relative to
ﬁreﬂy luciferase (transfection control). The luminescence
was determined using a Veritas luminometer (Turner
BioSystems, Inc. Sunnyvale, CA, USA). Results are
presented in relative light units and the SD is indicated
with error bars as shown in the graph data.
Northern analyses
Total RNA was isolated using RNA STAT-60
(TEL-TEST B Inc., Friendswood, TX, USA) according
to the manufacturer’s instructions. Fifteen microgram
of total RNA were fractionated in 8M–6% PAGE,
and transferred onto a Hybond-N+ membrane
(Amersham Pharmacia Biotech).
32P-radiolabeled 21-mer
probes complementary to the siRNA-antisense sequences
were used for the hybridization reactions, which
were performed for 16h at 378C. A 21-mer DNA
oligonucleotide was electrophoresed alongside the
RNA samples and used as a size marker and
hybridization control (not shown). For TRBP detection,
30mg RNA was fractionated on a 1% MOPS agarose gel,
transferred on a Hybond-N+ membrane and hybridized
with a
32P labeled probe complementary to TRBP
overnight at 378C.
Immunodepletion assay
Conﬂuent HEK293 cells in a 10cm dish were harvested
with 1  PBS after trypsinizing and resuspended in 0.5ml
of Buﬀer D (20mM HEPES, pH 7.9, 0.2mM EDTA,
0.5mM DTT, 50mM KCl, 10% Glycerol and 0.2mM
PMSF). The cells were sonicated for 15s in ice water,
and the supernatant was collected following 5min
centrifugation.
The immunodepletion was carried out by incubating
100ml of the extract with 30ml of anti-TRBP antibody (27)
or 30ml( 2 mg/ml) of anti-b-tubulin (Abcam Inc.,
Cambridge, MA, USA) antibody. Following overnight
incubation at 48C, 30ml of protein A agarose beads
(Upstate USA, Inc. Chicago, IL, USA) were added
and incubated for 1.5h at 48C with gentle agitation.
Following the removal of the beads by a brief centrifuga-
tion, 3ml of the supernatant were resolved in a 10%
SDS-PAGE for western blot analyses, and 10ml were
used for the electrophoretic mobility gel shift assay.
The pellet beads were boiled with 25mlo f2   SDS loading
buﬀer and 10ml were resolved alongside the supernatant
sample for western blot analyses. After transferring
proteins overnight, the PVDF membranes were blocked
with 5% milk in 1  PBS for 2h at room temperature
and washed with 1  PBST for 10min three times.
Primary and secondary antibody incubations were carried
out each for 1.5h in 5% milk in 1  PBST at room
temperature followed by washing with 1  PBST
for 10min three times. The membranes were rinsed with
1  PBS for 5min before drying. The secondary antibody
labeled with a 700 channel dye, anti-rabbit-680nm,
was used to detect rabbit polyclonal anti-TRBP Ab672
and b-tubulin.
Gel shift assays
For each reaction, 10ml of the TRBP or b-tubulin
immunodepleted cell extract was incubated with 10fmol
of 50 end-labeled siRNA for 30min at room temperature.
The samples were mixed with 2  native gel loading dye
and resolved in a 5% non-denaturing polyacrylamide gel
for 3h at 200V at 48C. The HEK 293 total cell extract and
the tubulin immunodepleted cell extract were used as
controls.
P24 assays
The human T cell line CEM was maintained in RPMI
1640 medium supplemented with 10% FBS. A total of
1 10
6 transduced CEM T cells were infected with HIV-1
strain IIIB at an MOI of 0.01. After overnight incubation,
cells were washed three times with Hanks’ balanced salts
solution and cultured in medium with R10 (RPMI 1640
plus 10% FBS). At designated time points, culture
supernatants were collected for p24 analyses (HIV-1 p24
antigen EIA kit, Beckman Coulter Inc.).
5156 Nucleic Acids Research, 2007, Vol. 35, No. 15RESULTS
Competition forRNAi components by co-transfected
ShRNAs
We have been interested in investigating the possibility
that in the presence of multiple interfering RNAs, the
saturation of RNAi components could diminish the
activity of a particular sh or siRNA and generate
misleading results. Most importantly, the degree of
saturation could be such as to interfere with the
endogeneous microRNA pathway, thus disrupting poten-
tially critical regulatory functions in the cell. To test this
possibility, we selected a series of shRNAs (shL, shVif,
shSII, shTAT, shSI) and co-transfected each with a FLT
and an anti-ﬁreﬂy-luciferase shRNA (Luc), which routi-
nely generates  90% down-regulation of the target
(Figure 1a). Each shRNA was also co-transfected alone
with the luciferase target (constructs 2–6, Figure 1a) to
monitor any non-speciﬁc reduction or increase of lucifer-
ase expression. The results clearly show that there is a
direct competition among non-related shRNAs
(Figure 1a). The degree of competition varies with the
shRNA used in the co-transfection. The down-regulation
of Luc was reduced by co-transfected, non-speciﬁc
shRNAs from 10 to 60%, yielding in two cases only
30% down-regulation of the luciferase target (Figure 1,
a Luc+shSI and Luc+shTAT) without any targeting of
RNAi components and/or presumably other cellular
genes. Northern analyses of total RNA from cells
transfected with these shRNA constructs did not show a
correlation between the degree of competition and
their intracellular expression levels (Figure 1, compare a
and b). Thus, competition must be dictated by the ability
of each shRNA to be processed into siRNA and
incorporated into RISC. Many parameters have been
analyzed in the literature that can improve shRNA designs
and possibly their incorporation into RISC (28). However,
none of the popular rules for the optimal shRNA
design can explain the diﬀerent levels of competition
exerted by each shRNA with the Luc shRNA construct
(Supplementary Data).
Although the relative intracellular expression of each
shRNA could not by itself explain the degree of
competition for each of the shRNAs, the total amount
of shRNA present in the cell can render Exportin 5 rate
limiting and aﬀect the overall shRNA activity. To test this
possibility, we co-transfected low concentrations (either
12.5 or 50ng) of three irrelevant shRNA expression
plasmids (shL, shSII and shSI) with equal amounts of
the Luc shRNA construct and its luciferase target.
As expected, the higher amount of shRNAs present in
the cell increased the competition while keeping the
relative strength of each shRNA as a competitor
unchanged (Figure 2a). The Luc shRNA showed the
same ability to down-regulate the target when 12.5, 25 or
50 total ng were transfected with the luciferase target
(Figure 2a, Luc-12.5, Luc-25, Luc-50). A double-stranded
RNA stem-loop expressing construct (a mutated HIV
TAR element that retains its structure) was also co-trans-
fected with the Luc shRNA and the luciferase target to
show that the competition is speciﬁc to shRNAs. The U6
TAR element is highly expressed in cells (not shown)
yielding levels of cellular transcripts that are comparable
to any of the shRNAs tested in these experiments.
As shown in Figure 2a, the TAR element did not
signiﬁcantly aﬀect the eﬃcacy of the Luc shRNA even
when transfected at a 1:3 ratio (50ng of Luc and 150ng
TAR). To test if the competition persists when the
shRNAs are present in a linear range we performed a
dose response curve using the Luc shRNA and the shSII
as a competitor (Figure 2b). We used 1, 3, 5, 12.5 and
25ng of shLuc in a luciferase down-regulation assay to
select the lowest amount of shRNA that still achieved
Figure 1. Irrelevant shRNA sequences compete with a luciferase-
directed shRNA and reduce its ability to down-regulate the target. (a)
FLT is a U1 expressed ﬁreﬂy luciferase gene, shL is targeted against the
EnvPb1 retrovirus envelope gene, shVif is targeted against the Vif gene,
shSII against sequences present in the HIV-Rev, shTAT is designed
against the HIV Tat gene and shSI is directed against both TAT and
Rev genes. The shRNA Luc is targeted to a sequence present in the
coding region of the ﬁreﬂy luciferase gene. The irrelevant shRNAs were
transfected with the luciferase target to monitor non-speciﬁc eﬀects
(constructs 2–6). FLT (construct 1) indicates the luciferase target
transfected alone. The Bluescript vector was used to adjust the total
amount of DNA transfected to be the same in each sample. Fifty
nanogram of the ﬁreﬂy luciferase target and 50ng of the shRNA
constructs were used for these transfection reactions. The luciferase
units were calculated by comparing each experimental sample to its
own control. A Renilla luciferase plasmid was co-transfected in each
sample as transfection control and used to normalize the ﬁreﬂy
luciferase units. (b) Northern analysis of total RNA from 293 cells
transfected with the relevant shRNAs as indicated on the top of the gel.
Probes complementary to the guide sequence corresponding to each
shRNA were used to detect the processed siRNA products (siRNA). A
probe complementary to the endogenous U6 small nuclear RNA
(U6snRNA) was used as internal control for the amount and integrity
of the RNA loaded in each lane.
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these results, we co-tranfected 5ng of shLuc with
increasing amounts of the shSII competitor. The results
show that even 1ng of added competitor is able to reduce
the activity of shLuc (Luc-5+shSII-1, Figure 2b).
SiRNAs competefor incorporation into RISC
The observation that the shRNA competition increases
with the total amount of transfected shRNA could be
explained by the increasing saturation of Exportin 5,
although the diﬀerent relative strengths of each shRNA
to compete against the shLuc when used in equal
amounts suggest that they are more likely due to a
preferential incorporation into RISC. Moreover, the
shRNA can also compete when used in non-saturating
conditions (Figure 2b). However, to bypass Exportin 5
we repeated the co-transfection experiment using
synthetic siRNAs (siH3, siH6 and siH1; Figure 3a). The
luciferase target was transfected alone or with each
synthetic siRNA (Figure 3a). The results of this experi-
ment show that the synthetic siRNAs were able to aﬀect
the down-regulation of the luciferase target when
co-transfected with the Luc construct. Similar to what
was shown with the shRNAs, the siRNAs competed to
diﬀering degrees with the Luc shRNA. Since synthetic
siRNAs do not need to be transported from the nucleus to
the cytoplasm for their function and their activity is not
aﬀected by Exportin-5 (20), the observed competition
must be at the level of incorporation into RISC. Although
a recent report shows that synthetic siRNAs can
potentially shuttle from the cytoplasm back into the
nucleus using Exportin-5 (29), this should not be a
major competition pathway for synthetic siRNAs.
Therefore, these results show that sh and siRNAs
compete at the level of incorporation into RISC
but may also compete for the Exportin 5 pathway to
some extent.
Shand siRNAs compete forExportin 5
To characterize any contribution made by the saturation
of Exportin-5 on the competition detected among inter-
fering RNAs, we included a plasmid-expressing Exportin-
5 in the co-transfection experiments. It has previously
been shown that co-transfecting Exportin-5 relieves the
saturation of transport and improves shRNA cleavage
of its target (19,24). As expected, our results show that
the overall activity of shLuc is improved, but competition
among the diﬀerent sequences still persists (Figure 3b).
It should be noted that for siRNAs, the eﬀect could be
indirect, and based only on more eﬃcient export of shLuc.
Micro RNAs do not competeforRNAi components
Our results show that when diﬀerent exogenously supplied
interfering RNAs are introduced into cells, competition
for export and incorporation into RISC can decrease or
completely block the activity of some RNAi triggers.
These ﬁndings suggest that transfected siRNAs and
shRNAs can also compete with endogenous
microRNAs. To test this hypothesis, we inserted the
siRNA directed against the site II HIV-rev-1 sequence
(SII) into the backbone of the mir-30 microRNA. We
made two diﬀerent versions of this microRNA, one
containing the entire wild-type backbone (Mir-B, and
the other with some additional mutations designed to
Figure 2. Diﬀerent shRNA sequences compete with diﬀerent strengths
against the Luc shRNA. (a) Diﬀerent concentrations of irrelevant
shRNA-expressing plasmids (shL, shSII, shSI) were co-transfected with
the ﬁreﬂy luciferase target (FLT) and the speciﬁc anti-luciferase shRNA
(Luc). The amount used in each transfection is indicated in ng (12.5, 25,
50 or 150). The luciferase units for each sample were calculated as
described in Figure 1 and in the Materials and Methods section. Each
irrelevant shRNA was transfected independently with the luciferase
target to monitor non-speciﬁc eﬀects. Each Luc co-transfection
experiment is normalized to its corresponding target-irrelevant control
and to the Renilla luciferase transfection control. However, for
convenience only one bar is shown to represent the target for each
group and it is indicated by FLT+Irr (Irrelevant). Bluescript was used
to adjust the total amount of DNA transfected in each sample. TAR
indicates the co-transfection of a U6 construct expressing a mutated
HIV-1 TAR structure (see text). (b) Non-saturating amounts of
shRNAs can still compete for incorporation into RISC. A titration
of U6 shLuc (Luc) was used to establish a concentration in the linear
range for activity (left side of the chart). Five nanogram of U6sh Luc
were then selected to be co-transfected with increasing amounts of a
shRNA competitor (shSII) (right side of the chart). The numbers 1–25
indicate the amount in nanograms used in the reactions.
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CG). Both microRNAs are processed (Figure 4c and data
not shown) and are eﬀective in down-regulating a RLT
which contains the corresponding complementary target
sequence within its 30 UTR (Mir-B, Mir-CG; Figure 4a).
When these microRNAs were co-transfected with
an irrelevant shRNA-expressing construct (shSI), their
inhibitory activity was dramatically reduced (Mir-
B+shSI, Mir-CG+shSI; Figure 4a). Conversely, the
microRNA constructs did not exert signiﬁcant inhibition
on the activity of shRNAs as shown by co-transfecting
Mir-B and Mir-CG with a U6 shRNA targeting the
ﬁreﬂy luciferase gene (compare Luc to Luc+Mir-B,
Luc+Mir-CG; Figure 4b). Importantly, the guide
sequence expressed by the microRNA becomes a good
competitor when it is expressed in the form of a shRNA
(shSII, Figure 1a).
Finally, when Mir-B and Mir-CG were co-transfected
with an irrelevant microRNA-expressing construct (Mir-
Irr), there was no signiﬁcant change in their ability to
down-regulate their target (Mir-B+Mir-Irr, Mir-
CG+Mir-Irr; Figure 4a), indicating that perhaps the
safest method for down-regulation of cellular targets is to
express the siRNA of choice within a microRNA
backbone.
To test if the diﬀerences among sh and microRNAs in
their ability to compete resides primarily with their levels
of expression, we repeated the competition experiment
using concentrations that would generate comparable
amounts of mature sequences as determined by Northern
blot analysis (Figure 4c). A 4-fold excess of mirCG over
shSII was used for the northern blot. Based on the
diﬀerences in the processed SII sequence, which is
expressed from both constructs, a 100-fold excess of
mirCG over shSII was used in a competition assay
(Figure 4c). The data show that a siRNA sequence is
not an eﬀective competitor when expressed from a
microRNA and yet it is very proﬁcient in down-regulating
its target even when transfected at lower concentrations
(Figure 4a).
Si andshRNAs can competewithendogenous microRNAs
To conﬁrm that si and shRNAs are able to interfere with
the microRNA regulatory activities in an intracellular
environment, we constructed a stable clonal cell line with
an integrated EGFP gene that includes the target site for
mir21at its 30 end (HCT116-GFPmiR21). In this cell line,
the EGFP gene is silenced by the endogenous expression
of the mir21 microRNA. Any inhibition with the
processing, transport and/or incorporation of mir21
would cause a reactivation of EGFP expression. It has
previously been shown that 20O-Me-oligonucleotides
(Antagomirs) can block microRNA activity when
designed to bind the microRNAs’ guide sequences
(30,31). As expected, transfection of an Antagomir fully
complementary to the mir21 guide sequence in the
HCT116-GFPmiR21 cells reactivated EGFP ﬂuorescence
by blocking the activity of the endogenous mir21 (Mir-21–
20 O-Me, Figure 4d), while an irrelevant Antagomir used
as control did not have any eﬀect on the level of
ﬂuorescence (IRR-20O-Me, Figure 4d). Both the non-
speciﬁc sh and siRNAs were able to increase EGFP
ﬂuorescence, demonstrating that these constructs can
interfere with the endogenous microRNA pathway
(shSII, siH1, Figure 4d). However, when the same
siRNA guide sequence was expressed from a microRNA
backbone, it did not aﬀect the mir21 activity, as shown by
the lack of EGFP ﬂuorescence (Mir-CG, Figure 4d). Two
additional microRNA constructs were transfected in
HCT116-GFPmiR21 with the same experimental outcome
(data not shown).
To conﬁrm that competition can alter the eﬃcacy of
shRNAs when used in a combinatorial fashion, we tested
Figure 3. (a) Synthetic siRNAs can reduce the ability of a shRNA to
down-regulate its target. A 10nM concentration of each synthetic
siRNA (siH3, siH6 and siH1) was co-transfected with the ﬁreﬂy
luciferase target (FLT) independently or together with the anti-ﬁreﬂy
shRNA (Luc). The ﬁreﬂy luciferase units were normalized against
Renilla luciferase, which was used as transfection control. (b) Over-
expression of Exportin-5 decreases shRNA competition but does not
eliminate competition among interfering RNAs. Twenty nanomolar of
each synthetic siRNA (siH3, siH6, siH1) or 50ng of each shRNA
construct (shL, shSII, shSI) were co-transfected with the luciferase
target and the Luc shRNA with or without 100ng of the Exportin-5-
expressing plasmid (Exp-5) as indicated in the ﬁgure (+Exp-5, -Exp-5).
Fireﬂy luciferase units were calculated as previously described.
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combination with two other shRNAs (shSII+2). CEM
cells were stably transduced with a single shRNA or with
three diﬀerent shRNAs each independently expressed
from a separate U6 promoter and then infected with
HIV IIIB. The results from these experiments show that
shSII results in potent inhibition of HIV replication
whereas when combined with two additional shRNAs
provide protection for the ﬁrst seven days, but viral
replication breaks through after one week (Figure 5a). The
loss of inhibitory activity by the triple construct was not
due to loss of expression, since the levels of siRNAs were
comparable for the single shRNA and triple constructs
(Figure 5b). The most plausible explanation for the viral
breakthrough in the triple construct expressing cells is
competition among the shRNAs/siRNAs for export and
incorporation into RISC, allowing the virus to escape
RNAi surveillance and replicate.
Figure 4. ShRNAs reduce the activity of microRNA constructs while microRNAs are not eﬀective competitors. (a) A target site for the Mir-B and
Mir-CG is inserted in the 30 UTR of the Renilla luciferase gene, which is used as reporter construct in this experiment (RLT). Co-transfection of an
irrelevant shRNA (shSI) nearly abolished the activity of the microRNAs (compare Mir-B and Mir-CG with Mir-B+shSI, Mir-CG+shSI) while an
irrelevant microRNA (Mir-Irr) had no eﬀect on Mir-B and Mir-CG (Mir-B+Mir-Irr and Mir-CG+Mir-Irr). The Renilla luciferase units were
normalized against the ﬁreﬂy luciferase which was co-transfected with the experimental samples and used as an internal transfection control. (b)A n
irrelevant shRNA (shSI) strongly reduces the eﬃcacy of Luc (Luc versus Luc+shSI), but an irrelevant microRNA (Mir-B or Mir-CG) did not have a
signiﬁcant eﬀect on the activity of the speciﬁc shRNA (compare Luc versus Luc+Mir-B and Luc+Mir-CG). The units of the ﬁreﬂy reporter target
were normalized against the Renilla luciferase which was used as internal transfection control. (c) Left; northern analysis of total RNA from 293 cells
transfected with shSII or mirCG. A 4-fold excess of mirCG over shSII was used for the transfection. The probe is complementary to the mature SII
which is the sequence expressed from both constructs. A probe complementary to the endogenous U6snRNA (U6) was used as control. Right; shSII
or mirCG were used as competitors against the shLuc construct. Five hundred nanogram or 5ng of mirCG and shSII respectively were used to
compete against 5ng of shLuc. (d) Synthetic si and shRNAs, but not expressed microRNAs, can compete with the endogenous microRNA pathway.
A stable clonal cell line with an integrated EGFP gene that includes the target site for the endogenous mir21at its 30 end (HCT116-GFPmiR21) was
mock transfected (Lip-2000) or transfected with: (i) a 20O-Me-oligonucleotide designed to bind and block mir21 activity (Mir-21–20O-Me), (ii) an
irrelevant 20O-Me-oligonucleotide to test for non-speciﬁc reactivation of EGFP (IRR-20O-Me), (iii) a microRNA construct expressing the SII guide
sequence (Mir-CG), (iv) an shRNA construct expressing the SII guide sequence (shSII) and (v) a synthetic siRNA (siH1). EGFP reactivation
indicates interference with the activity of the endogenous mir21.
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Our experiments show that each siRNA sequence
competes to a diﬀerent extent with other siRNAs and
shRNAs. Incubation of
32P end-labeled siRNAs in
HEK293 cytoplasmic extracts results in the formation of
a gel-shifted complex using native polyacrylamide gel
electrophoresis (Figure 6a, lane 2). The amount of binding
in this assay is directly proportional to the intracellular
eﬃcacy of the siRNAs analyzed (Sakurai et al., unpub-
lished data). We speculated that TRBP, a double-stranded
RNA-binding protein that has been shown to be part of
the minimal RISC (26,32), could contribute to the loading
of siRNA guide sequences into RISC and that it would be
part of this complex. Depletion of TRBP from the cellular
extracts (anti-TRBP) resulted in a marked reduction of
siRNA complex formation (Figure 6a, lanes 4), while
depletion of b-tubulin (anti-b-tubulin), which was used as
control, had no eﬀect (Figure 6a, compare lanes 2 and 3).
Identical results were obtained when depletion for b-actin
was used as control (data not shown). Western analyses of
the extracts showed that depletion of both TRBP and
b-tubulin were nearly complete (Figure 6b). However, the
small amount of residual gel-shifted complex may reﬂect
incomplete removal of TRBP or could be due to binding
of the siRNAs by other components of RISC. We
repeated our competition experiment using cells in which
TRBP levels were reduced by siRNA-mediated targeting
of the TRBP2 mRNA (see Materials and Methods
section). TRBP levels were reduced by  80% as deter-
mined by western (Figure 6c) and northern (data not
shown) analyses. Depletion of TRBP resulted in more
equivalent competition by each shRNA sequence (shL,
shVif, shSII, shTAT, shSI) or siRNA sequence (siH3,
siH6, siH1), but competition with shLuc still persisted
(Figure 6d).
DISCUSSION
We have shown competition between siRNAs and
shRNAs when they are co-transfected into cultured cells.
This competition is partially dependent upon saturation of
Exportin-5 by the shRNAs and is largely sequence
independent. The activity of a luciferase-targeted si or
shRNA can be compromised by the ability of another
siRNA to be preferentially loaded into RISC.
The competition among shRNAs raises some important
issues. Our data show that both siRNAs and shRNAs can
compete with the endogenous microRNA pathway
(Figure 4d) thus posing the potential for perturbation
of endogenous cellular miRNA processes. In a recent
publication, Grimm et al. (19) reported that some shRNA
sequences were able to block the activity of the liver-
speciﬁc miR122 and additionally caused severe liver
toxicity and death of some of the treated mice. The
authors attributed this adverse eﬀect to saturation of
Exportin-5, postulating that despite being expressed from
the same AAV vector backbone, some sequences were
expressed at higher levels and were more toxic. Our results
demonstrate that competition with endogenous
microRNAs can be a general phenomenon and that
Exportin-5 is only one of the components involved, as
shown by the inability to fully restore the U6sh-luciferase
activity when Exportin-5 was ectopically expressed
(Figure 3b). Moreover, synthetic siRNAs, which do not
rely on Exportin-5 for their transport, can still aﬀect the
activity of both shRNAs (Figure 3a) and microRNAs
(Figure 4d). These results indicate that the ability of a
speciﬁc sequence to compete is also determined by its
ability to be loaded into RISC. Interestingly, the relative
competitive strength of the synthetic siRNAs with the Luc
shRNA correlated with their eﬃcacy to down-regulate
their cognate targets, which in turn is directly proportional
to the complex formation in cell extracts (Sakurai et al.,
unpublished data). These results are consistent with a
previously published study (33) in which competition was
detected between heavily modiﬁed and unmodiﬁed syn-
thetic siRNAs. The competition was found to correlate
with the potency of the siRNAs and it was attributed to a
possible saturation of the export system or competition for
other RISC components.
The aﬃnity of each sequence for one or more RNAi
component(s) may determine the eﬃciency of loading of
that sequence into RISC, thereby potentiating the
competition with other sh/siRNAs and miRNAs. TRBP
is a double-stranded RNA-binding protein that has been
shown to associate with both Dicer and Ago-2 (26,32).
Figure 5. (a) p24 HIV challenge assay shows escape from RNAi when
multiple shRNAs are simultaneously expressed. Stable CEM cells
expressing shSII (shSII) are protected from HIV infection. This
protection is lost when two other shRNAs are expressed simulta-
neously. Cells transduced with the vector backbone (Vect) are used as
control. (b) Northern analysis shows comparable expression of shSII in
transduced cells when expressed alone (shSII) or in combination
with two other shRNAs (shSII + 2). A probe complementary to the
mature SII RNA sequence was used to detect the processed siRNA.
Probes for the other two shRNAs also revealed robust expression
(data not shown).
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executions steps of RNAi (26) and that it identiﬁes the
guide strand prior for passage on to Ago-2 (34). Our data
reveal that cellular down-regulation of TRBP results in
loss of diﬀerential competition by the various sh/siRNAs,
although competition per se still persists (Figure 6d),
perhaps via a bypass mechanism for incorporation into
the Ago2-binding domain. Our results support the role of
TRBP as a sensor for the RISC loading or Ago-2 handoﬀ
(26). However, it is possible that TRBP does not act alone
and loading may include other RISC proteins.
In our experimental system, sequences expressed from
a microRNA backbone are poor competitors relative
to shRNA or siRNAs of the same sequences (Figure 4).
Two diﬀerent sequences were expressed from three
diﬀerent microRNA backbones and none of them was
able to compete (Figure 4 and data not shown) despite
the fact that these sequences were still eﬀective in RNAi.
The overall level of shRNA expression does not seem
to be the primary reason for this lack of competition
(Figure 4c), which is probably determined by the overall
kinetics of incorporation. Since miRNAs are being
shunted through the endogenous miRNA-processing
pathway, this may slow their entry into RISC relative to
highly expressed shRNAs and transfected siRNAs.
Si and sh-RNAs are routinely used to down-regulate
cellular genes, siRNA libraries have been widely employed
to screen for gene function (9–11), and siRNAs are
Figure 6. (a) Gel shift assay shows loss of complex formation when TRBP depleted cellular extracts are mixed with labeled siRNAs. A
32P end-
labeled anti-EGFP siRNA (without cellular extracts in lane 1) was mixed with: lane 2, total cellular extract; lane 3, extracts depleted of b-tubulin;
lane 4 extracts depleted of TRBP. (b) Western detection of TRBP and b-tubulin after immunodepletion. Extracts were treated with TRBP or
b-tubulin antibodies and precipitated as described in the Materials and Methods section. S, supernatant; P, pellet. The supernatant fractions show to
be substantially depleted of TRBP or b-tubulin and were subsequently used in the gel shift assay for detection of complex formation (a). (c) Western
analyses of lysates from cells treated with (+) or without ( ) TRBP siRNA as described in Materials and Methods section. Lysates from cells
transfected with a TRBP-expressing plasmid (TRBP) were used for size determination. Detection of b-tubulin was used as an internal control.
(d) TRBP down-regulation eliminates the diﬀerential competition among interfering RNAs. Twenty nanomolar of each synthetic siRNA (siH3, siH6,
siH1) or 50ng of each shRNA construct (shL, shVif, shSII, shTAT, shSI) were co-transfected with the ﬁreﬂy luciferase target (FLT) and the Luc
shRNA in cells that were pre-treated for 5 days with a siRNAs targeted against TRBP. Fireﬂy luciferase units were calculated as previously
described.
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degeneration, respiratory syncitial virus (SRV) infection
and acute kidney failure. The potential for competition of
the clinically applied siRNAs with endogenous miRNAs
is a concern as is the competition among combinations of
si/shRNAs. Due to the rapid emergence of resistance
mutations in viruses such as HCV and HIV, the use of
combinations of sh/siRNAs represents a potential
mechanism for circumventing this problem. If one of the
siRNAs is more eﬃciently loaded into RISC, it could
compromise the eﬀectiveness of one or more of the other
siRNAs. For example, our data clearly show that an
eﬀective shRNA targeted against the HIV-1 rev gene,
when combined with two other hairpins, no longer
provides stable, long-term inhibition of HIV replication
(Figure 5). This result is consistent with previous ﬁnding
by Nishitsuji et al. (35), which showed a negative eﬀect on
shRNA antiviral activities when used in a combinatorial
fashion. However, based upon our ﬁndings, concern about
obstructing the endogenous RNAi machinery can poten-
tially be overcome by modifying the siRNA expression
system to produce a microRNA, or by combining si and
shRNAs that do not compete with one another. By ﬁnding
siRNA/target combinations that work at the lowest
possible concentrations, it should be possible to mitigate
the potential for competition with endogenous miRNAs
or among combinations of applied si/shRNAs.
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